Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability
暂无分享,去创建一个
Rohit Bakshi | Shahamat Tauhid | Renxin Chu | Shelley Hurwitz | R. Chu | R. Bakshi | S. Tauhid | S. Hurwitz
[1] C. Guttmann,et al. Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[2] Massimo Filippi,et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes , 2008, NeuroImage.
[3] B. J. Winer. Statistical Principles in Experimental Design , 1992 .
[4] R. Bakshi,et al. Measurement of Brain and Spinal Cord Atrophy by Magnetic Resonance Imaging as a Tool to Monitor Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[5] M. Dwyer,et al. Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.
[6] R. Bakshi,et al. Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review , 2017, JAMA neurology.
[7] E. Waubant,et al. Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis , 2016, Journal of the Neurological Sciences.
[8] Hans Lassmann,et al. Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.
[9] Rohit Bakshi,et al. Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[10] Hon-Man Liu,et al. Reproducibility of Brain Morphometry from Short-Term Repeat Clinical MRI Examinations: A Retrospective Study , 2016, PloS one.
[11] S. Reingold,et al. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.
[12] M. Schlamann,et al. First Clinical Study on Ultra-High-Field MR Imaging in Patients with Multiple Sclerosis: Comparison of 1.5T and 7T , 2009, American Journal of Neuroradiology.
[13] Hans Lassmann,et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.
[14] C. Crainiceanu,et al. Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling☆ , 2013, NeuroImage: Clinical.
[15] Robert L. Mason,et al. Statistical Principles in Experimental Design , 2003 .
[16] G. Tsivgoulis,et al. The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis , 2015, PloS one.
[17] Seth E. Bouvier,et al. Comparison of Multiple Sclerosis Lesions at 1.5 and 3.0 Tesla , 2003, Investigative radiology.
[18] Rohit Bakshi,et al. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis , 2017, The International journal of neuroscience.
[19] P. Kalavathi,et al. Methods on Skull Stripping of MRI Head Scan Images—a Review , 2016, Journal of Digital Imaging.
[20] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[21] F. Barkhof,et al. Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method , 2016, PloS one.
[22] Craig K. Jones,et al. Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology , 2015, Multiple sclerosis.
[23] J S Wolinsky,et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis , 2006, European journal of neurology.
[24] Anders M. Dale,et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths , 2009, NeuroImage.
[25] C. Poser,et al. Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.
[26] Rohit Bakshi,et al. Role of MRI in multiple sclerosis I: inflammation and lesions. , 2004, Frontiers in bioscience : a journal and virtual library.
[27] Xiao-Li Meng,et al. Comparing correlated correlation coefficients , 1992 .
[28] R. Bakshi,et al. Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. , 2010, Annals of neurology.
[29] R. Bakshi,et al. Corpus Callosum Atrophy Correlates with Gray Matter Atrophy in Patients with Multiple Sclerosis , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[30] Massimo Filippi,et al. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study , 2006, The Lancet Neurology.
[31] Rohit Bakshi,et al. Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models , 2015, NeuroImage: Clinical.
[32] C. Jack,et al. Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimer's Disease Neuroimaging Initiative , 2015, American Journal of Neuroradiology.
[33] Rohit Bakshi,et al. Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[34] J A Frank,et al. MRI T2 lesion burden in multiple sclerosis , 2006, Neurology.
[35] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[36] Sheena L. Dupuy,et al. The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis , 2016, Neurology and Therapy.
[37] D. Reich,et al. Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis , 2017, American Journal of Neuroradiology.
[38] C R G Guttmann,et al. Thalamic atrophy and cognition in multiple sclerosis , 2007, Neurology.
[39] D. Ramasamy,et al. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[40] D. Ontaneda,et al. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives , 2015, The Lancet Neurology.